

## Daftar Pustaka

- Alhazzani, W. *et al.* (2020) ‘Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)’, *Critical Care Medicine*, pp. E440–E469. doi: 10.1097/CCM.0000000000004363.
- Baum, A. *et al.* (2020) ‘REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters’, *Science (New York, N.y.)*, 370(6520), p. 1115. doi: 10.1126/SCIENCE.ABE2402.
- Berlin, D. A., Gulick, R. M. and Martinez, F. J. (2020) ‘Severe Covid-19’, *The New England journal of medicine*, 383(25), pp. 2451–2460. doi: 10.1056/NEJMCP2009575.
- Caly, L. *et al.* (2020) ‘The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro’, *Antiviral Research*, 178, p. 104787. doi: 10.1016/J.ANTIVIRAL.2020.104787.
- Cao, B. *et al.* (2020) ‘A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19’, *The New England Journal of Medicine*, 382(19), pp. 1787–1799. doi: 10.1056/NEJMOA2001282.
- Cao, Y. *et al.* (2020) ‘Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial’, *The Journal of Allergy and Clinical Immunology*, 146(1), p. 146. doi: 10.1016/J.JACI.2020.05.019.
- Cascella, M. *et al.* (2021) ‘Features, Evaluation, and Treatment of Coronavirus (COVID-19)’, *StatPearls*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK554776/> (Accessed: 29 November 2021).
- Cavalcanti, A. B. *et al.* (2020) ‘Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19’, *New England Journal of Medicine*, 383(21), pp. 2041–2052. doi: 10.1056/NEJMOA2019014.
- Chan, J. F. W. *et al.* (2020) ‘Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan’, *Emerging Microbes & Infections*, 9(1), p. 236. doi: 10.1080/22221751.2020.1719902.

- Cook, T. M. *et al.* (2020) 'Consensus guidelines for managing the airway in patients with COVID-19: Guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetists', *Anaesthesia*, 75(6), p. 799. doi: 10.1111/ANA.E.15054.
- Coopersmith, C. M. *et al.* (2021) 'The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness', *Critical care medicine*, 49(4), pp. 598–622. doi: 10.1097/CCM.0000000000004895.
- Davoudi-Monfared, E. *et al.* (2020) 'A Randomized Clinical Trial of the Efficacy and Safety of Interferon  $\beta$ -1a in Treatment of Severe COVID-19', *Antimicrobial Agents and Chemotherapy*, 64(9). doi: 10.1128/AAC.01061-20.
- Eliana, S. S. (2016) 'Kesehatan Masyarakat', *Kesehatan masyarakat*, p. 2. Available at: <http://bppsdmk.kemkes.go.id/pusdiksdmk/wp-content/uploads/2017/08/Kesehatan-Masyarakat-Komprehensif.pdf> (Accessed: 27 November 2021).
- Gandhi, R. T., Lynch, J. B. and del Rio, C. (2020) 'Mild or Moderate Covid-19', *The New England journal of medicine*, 383(18), pp. 1757–1766. doi: 10.1056/NEJMCP2009249.
- Gottlieb, R. L. *et al.* (2021) 'Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial', *JAMA*, 325(7), p. 644. doi: 10.1001/JAMA.2021.0202.
- Grieco, D. L. *et al.* (2021) 'Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial', *JAMA*, 325(17), p. 13. doi: 10.1001/JAMA.2021.4682.
- Grief, S. N. and Loza, J. K. (2018) 'Guidelines for the Evaluation and Treatment of Pneumonia', *Primary Care*, 45(3), p. 503. doi: 10.1016/J.POP.2018.04.001.
- Group, T. R. C. (2020) 'Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19', *The New England Journal of Medicine*, 383(21), pp. 2030–2040. doi: 10.1056/NEJMOA2022926.

- Hasanah, K., Andrajati, R. and Supardi, S. (2020) 'Kontribusi Kelengkapan Pengisian Formulir Rekonsiliasi Obat terhadap Penggunaan Obat Rasional pada Pasien Rawat Inap di RSUD X Bekasi', *Jurnal Kefarmasian Indonesia*, 10(1), pp. 11–18. doi: 10.22435/jki.v10i1.1839.
- Huet, T. *et al.* (2020) 'Anakinra for severe forms of COVID-19: a cohort study', *The Lancet Rheumatology*, 2(7), p. e400. doi: 10.1016/S2665-9913(20)30164-8.
- Jain, V. *et al.* (2021) 'Pneumonia Pathology', *StatPearls*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK526116/> (Accessed: 28 December 2021).
- Joyner, M. J. *et al.* (2020) 'Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients', *Mayo Clinic Proceedings*, 95(9), p. 1888. doi: 10.1016/J.MAYOCP.2020.06.028.
- Kalil, A. C. *et al.* (2021) 'Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19', *The New England Journal of Medicine*, 384(9), pp. 795–807. doi: 10.1056/NEJMOA2031994.
- Kementrian Kesehatan (2004) *Keputusan Menteri Kesehatan Republik Indonesia Nomor 1197/MENKES/SK/X/2004 tentang Standar Pelayanan Farmasi di Rumah Sakit*. Available at: <https://persi.or.id/wp-content/uploads/2020/11/kmk11972004.pdf> (Accessed: 14 February 2022).
- Kementrian Kesehatan (2017) 'Permenkes No. 72 Tahun 2016 tentang Standar Pelayanan Kefarmasian Di Rumah Sakit [JDIH BPK RI]', pp. 55–56. Available at: <https://peraturan.bpk.go.id/Home/Details/114491/permenkes-no-72-tahun-2016> (Accessed: 27 November 2021).
- Lescure, F. X. *et al.* (2021) 'Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial', *The Lancet. Respiratory Medicine*, 9(5), p. 532. doi: 10.1016/S2213-2600(21)00099-0.
- Michot, J. M. *et al.* (2020) 'Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report', *Annals of Oncology*, 31(7), p. 964. doi: 10.1016/J.ANNONC.2020.03.300.
- Richardson, P. *et al.* (2020) 'Baricitinib as potential treatment for 2019-nCoV acute respiratory disease', *Lancet (London, England)*, 395(10223), p. e31. doi:

10.1016/S0140-6736(20)30304-4.

Roschewski, M. *et al.* (2020) 'Inhibition of Bruton tyrosine kinase in patients with severe COVID-19', *Science Immunology*, 5(48). doi: 10.1126/SCIIMMUNOL.ABD0110.

Wang, M. *et al.* (2020) 'Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro', *Cell Research*, 30(3), p. 271. doi: 10.1038/S41422-020-0282-0.